May 01, 2016 - MM&M - Medical Marketing and Media

Print Issue: May 01, 2016

10. Sanofi

The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent’s sales to date haven’t awed analysts.

8. Amgen

As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer’s future.